Abstract
Reduced cognitive abilities are often characterized by an impairment of flexibility—the ability to switch from learned rules to new modalities. While drugs targeting the dopamine transporter (DAT) are used to enhance cognition, many lack specificity, blocking noradrenaline and serotonin transporters and leading to unwanted side effects like increased impulsivity. This study tested CE-123, a newly synthesized compound with high DAT specificity, in male rats. Using an attentional set-shifting task (ASST) and a 5-choice serial-reaction time task (5-CSRTT), researchers found that CE-123 (0.3 and 1.0 mg/kg) significantly improved extra-dimensional shifts, indicating increased cognitive flexibility. Unlike R-Modafinil, which increased premature responses (impulsivity) during long intertrial intervals, CE-123 maintained stable impulsivity levels. These findings suggest that CE-123 enhances cognitive flexibility without the behavioral costs associated with traditional stimulants.
Introduction
Cognitive flexibility is a cornerstone of executive function, allowing individuals to adapt their behavior in response to changing environmental demands. This ability is frequently compromised in aging and various neuropsychiatric disorders. Pharmacological interventions often target the dopamine transporter (DAT) to boost synaptic dopamine levels; however, many current DAT inhibitors are "dirty drugs" that also affect norepinephrine (NET) and serotonin (SERT) transporters. This lack of selectivity can result in cardiovascular side effects and increased impulsivity.
To address this, researchers developed CE-123, a highly specific DAT inhibitor designed to act as a "cognitive sniper." The goal was to determine if high DAT specificity could decouple the cognitive benefits of dopamine modulation from the common side effect of heightened impulsivity.
Methodology
Chemical Synthesis and Pharmacological Profiling
The study began with the synthesis of racemic CE-123, followed by the separation of its S- and R-enantiomers. The compound's specificity was validated in vitro using HEK293 cells expressing human isoforms of DAT, NET, and SERT.
Behavioral Assays
Two primary behavioral models were used with healthy male Sprague-Dawley rats:
- Attentional Set-Shifting Task (ASST): This task measures cognitive flexibility by requiring rats to switch between different stimulus dimensions (e.g., odor vs. texture) to find a food reward. The critical measure is the "Extra-Dimensional (ED) shift," where the rat must abandon a previously successful rule for a new one.
- 5-Choice Serial Reaction Time Task (5-CSRTT): This task assesses visuospatial attention and impulsivity. Rats must wait for a light stimulus before responding. Responses made before the stimulus (premature responses) serve as a metric for impulsivity.
Results
Enhanced Cognitive Flexibility
In the ASST, rats treated with CE-123 at doses of 0.3 and 1.0 mg/kg required significantly fewer trials to master the ED shift compared to vehicle-treated controls. This indicates a clear improvement in the rats' ability to adapt to new rules. Interestingly, the lowest dose (0.1 mg/kg) did not produce a significant effect, suggesting a specific therapeutic window for cognitive enhancement.
Stability of Impulsivity and Attention
In the 5-CSRTT, the benchmark drug R-Modafinil (10 mg/kg) caused a significant increase in premature responses during challenging 10-second inter-trial intervals, indicating elevated impulsivity. In contrast, CE-123 at the same dose did not increase premature responses. General visuospatial attention and accuracy remained stable across all groups, confirming that the effects were specific to executive control rather than general arousal.
Discussion and Conclusion
The study demonstrates that CE-123 provides a significant advantage over existing DAT inhibitors by improving cognitive flexibility without inducing impulsivity. This suggests that flexibility and impulsivity may be regulated by different dopaminergic thresholds, and CE-123 effectively targets the "sweet spot" for mental agility.
Limitations and Future Directions
While promising, the study was limited to healthy male rats. Future research must include female subjects to account for sex-based differences in dopamine signaling. Additionally, while the acute benefits are clear, the effects of chronic administration on transporter regulation and the compound's efficacy in models of cognitive impairment (such as ADHD or age-related decline) remain to be explored.
Summary updated